Study the action of pycnogenol on glucose and lipid profile in type -2- diabetic patients

Rasha Zuhair, Dr.Amar Maola Hmod

Summary :

Pycnogenol *pinus pinaster Ait* (a water extract of polyphenolic compounds) was extracted from Iraqi pine bark and analyzed using high performance liquid chromatography (HPLC) coupled to ultra violet UV detection that was recorded at (254 nm).

Pycnogenol action on some biochemical parameters (glucose, total cholesterol (TC), triacylglycerol (TG), high density lipoproteins (HDL), low density lipoproteins (LDL), very low density lipoproteins (VLDL)) level was determined in (30) type -2- diabetic patients who treated with capsules (500 mg) of pycnogenol three times daily to examine the reactive role of pycnogenol against oxidative stress. The above biochemical parameters were measured in plasma before treatment with pycnogenol and after (1 week), (2 weeks) and (3 weeks) of treatment with this polyphenolic extract.

Our results have shown that glucose level was increased relatively for diabetic patients compared with control group (p<0.001) but after treatment with pycnogenol, glucose level would be decreased relatively (p<0.001) after (1 week), (p<0.001) after (2 weeks) and (p<0.05) after (3 weeks) of treatment with pycnogenol. Total cholesterol (TC) level increased relatively for diabetic patients compared with control group (p<0.001), but after treatment with this reactive extract (TC) level decreased relatively (p<0.001) after (1 week), (p<0.001) after (2 weeks) and (p<0.01) after (3 weeks) of treatment with pycnogenol. Triacylglycerol (TG) level was increased relatively for diabetic patients compared with control group (p<0.001), but after treatment with this antioxidant extract (TG) level decreased relatively (p<0.001) after (1 week), (p<0.001) after (2 weeks) and (p<0.01) after (3 weeks) of treatment with pycnogenol. High density lipoproteins (HDL) level was decreased relatively for diabetic patients compared with control group (p<0.001), but after treatment with pycnogenol (HDL) level increased relatively (p<0.01) after (1 week), (p<0.01) after (2 weeks) and (p<0.05) after (3 weeks) of treatment with pycnogenol. Low density lipoproteins (LDL) level increased relatively for diabetic patients compared with control group (p<0.001), but after treatment...
Study the action of pycnogenol on glucose and lipid profile in type 2 diabetic patients...

Rasha Zuhair, Dr. Amar Maola Hmod

with pycnogenol, (LDL) level decreased relatively (p<0.001) after (1 week), (p<0.001) after (2 weeks) and (p<0.01) after (3 weeks) of treatment with pycnogenol. Very low density lipoproteins (VLDL) level increased relatively for diabetic patients compared with control group (p<0.001), but after treatment with pycnogenol, (VLDL) level decreased relatively (p<0.001) after (1 week), (p<0.001) after (2 weeks) and (p<0.01) after (3 weeks) of treatment with pycnogenol.

Introduction :-

Pycnogenol (PYC) is a super antioxidant extract of pine bark. It mainly consists of a high reactive polyphenolic compounds called procyanidins. Additionally pycnogenol contains monomeric flavonoids such as catechin, taxifolin, and various phenolic acids like ferulic acid.\(^{(1,2)}\)

The role of pycnogenol as exceptional free radical scavenger is just beginning to emerge and the protective potential of pycnogenol is impressive to say the least. It is only a matter of time before scientific data support the fact that the family of nutrients is far more effective in its antioxidant capacity than previously assumed.\(^{(1,2,3)}\)

A number of pharmacological function award pycnogenol a prominent role for helping diabetic people to cope with their various health problems.\(^{(2,4)}\)

Pycnogenol appears to facilitate cellular uptake of glucose as it does not affect insulin levels.\(^{(1,3)}\)

Pycnopenol protects against oxidative stress in several cell systems by doubling the intracellular synthesis of anti-oxidative enzymes and by acting as a potent scavenger of free radicals that cause different diseases such as diabetes mellitus and its complications like atherosclerosis and heart disease. This group of compounds is like other polyphenols acts on special mechanism to decrease oxidative stress. This mechanism can be characterized by decreasing oxygen concentration in living cells, intercepting singlet oxygen and preventing first-chain initiation by scavenging initial radicals such as OH.\(^{(4,5)}\)

The procyanidins contained in pycnogenol may well become the most important nutritional breakthrough of the 21\(^{\text{st}}\) century.\(^{(1,2)}\)

Patients and Methods :-

- **Patients and materials:**
  Ethanol (80%) was used for pycnogenol extraction and methanol (30%) was used for high performance liquid chromatography (HPLC) analysis. Iraqi pine bark was used for pycnogenol extraction.

- **Extraction and analysis of Pycnogenol.**
  Pine bark (100 gm) was subjected to a series of extraction steps involved (100 ml) of ethanol\(^{(5)}\). The extraction was achieved using saxholet and then liquid evaporator was performed by rotator evaporator and lypholizer. Extraction percent was (75%). A very fine brownish colored, water soluble powder was identified by high performance liquid chromatography (HPLC 2010A / Shimdzo
Study the action of pycnogenol on glucose and lipid profile in type 2 diabetic patients... 
Rasha Zuhair, Dr.Amar Maola Hmod

Japan) coupled to ultra violet (UV) detection. The optimized conditions of HPLC for analysis were as follows:- The analytical column (octadecyl / silan column ODSc18) (12.5 cm long × 4mm i.d. and 5 µm particle diameter ), methanol (30%) as the mobile phase. Ultra violet (UV) detection was recorded at (254 nm) ,column temperature (25C) and injection volume is (20µL). The resulted polyphenolic compounds are :- procyanidin B1 , procyanidin B2 , catechin , procyanidin C2 , taxifolin and ferulic acid.the extraction and analysis were performed in minister of sciences and technology / center of chemicals researches.

- **Patients Groups:-**
  Blood Samples were collected from (30) type -2- diabetic patients with age in range of (40-65) years. These samples were collected from patients in the national center of diabetic treatment and researches in Mustansirya University in Baghdad cooperated with a specific laboratory called al –benok laboratory. This group compared with control group which consists of (thirty) healthy subject with age in range of (40-65) years.

- **Pycnogenol samples:-**
  Pycnogenol was in a form of capsules (500 mg ). These capsules were given to the patients three time daily and parameters were measured after (1 week), (2 weeks) and (3 weeks) of treatment.

- **Determination of glucose level in plasma.**
  Glucose level was determined in the sample by an enzymatic colorimeter test using glucose oxidase (GOD) and peroxidas (POD). The absorbance was recorded at (λ max =500 nm).

- **Determination of total cholesterol (TC) level in plasma.**
  An enzymatic procedure was used in the presence of peroxidase , cholesterol oxidase and cholesterol esterase. The detection was recorded at (λ max = 510nm).

- **Determination of triacylglycerol (TG) level in plasma.**
  A enzymatic procedure was used in the presence of lipase, glycerol kinase , glycerol -3- phosphate oxidase , peroxidase. The absorbance was recorded at (λ max=510 nm).

- **Determination of High density lipoproteins (HDL) level in plasma.**
  HDL was measured using Precipitation method. phosphotungestic acid and magnesium ion were used. The Absorbance was recorded at (λ max = 510 nm).

- **Determination of low density lipoproteins (LDL) and very low density lipoproteins (VLDL) levels in plasma.**
  LDL and VLDL levels were determined using using the equations below:-
Study the action of pycnogenol on glucose and lipid profile in type-2 diabetic patients...

Rasha Zuhair, Dr. Amar Maola Hmod

VLDL = TG / 5
LDL = TC – (HDL + VLDL)

Statistical analysis:
Statistical significance between means values of biochemical parameters (glucose, Total cholesterol(TC), triacylglycerol (TG), high density lipoproteins (HDL), low density lipoproteins (LDL), very low density lipoproteins (VLDL)) was evaluated by the student t.test in the text and tables. This statistical method was performed to determine the significance of the means between the control group and patients groups.

- Probability less than 0.05 (P<0.05) was considered to be significant.
- Probability less than 0.01 (P<0.01) was considered to be high significant.
- Probability less than 0.001 (P<0.001) was considered to be very high significant.

Results and Discussion:

(Figure 1): Pycnogenol action on fasting plasma glucose level where:
C: control group.
B: Patients group before treatment with Pycnogenol.
A1: Patients group after (1 week) of treatment with pycnogenol.
A2: Patients group after (2 weeks) of treatment with pycnogenol.
A3: Patients group after (3 weeks) of treatment with pycnogenol.

(Table 1): The effect of pycnogenol on the level of glucose in patients group in comparison with control group.

<table>
<thead>
<tr>
<th>Subject</th>
<th>No.</th>
<th>M ± S.D</th>
<th>t.test</th>
</tr>
</thead>
<tbody>
<tr>
<td>control</td>
<td>30</td>
<td>95±12.4</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>30</td>
<td>275±36.2</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>A1</td>
<td>30</td>
<td>200±18.3</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>A2</td>
<td>30</td>
<td>170±10.2</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>A3</td>
<td>30</td>
<td>150±7.5</td>
<td>P&lt;0.05</td>
</tr>
</tbody>
</table>

M: Glucose mean (mg/dL)
No.: number of patients.
S.D.: standard deviation.
Study the action of pycnogenol on glucose and lipid profile in type-2 diabetic patients...

Rasha Zuhair, Dr.Amar Maola Hmod

(Figure 1) and (table 1) represent the important action of pycnogenol extract on glucose level in type-2 diabetic patients. The plasma glucose in group B was increased (p<0.001) compared with control group (figure 1) and (table 1). This increasing could be explained as insufficient production of insulin from beta cells (insulin regulates glucose metabolism) or because of inability of body cells to use glucose ideally (insulin resistance), so glucose level would be elevated in the plasma.

After treatment with pycnogenol, glucose level was decreased relatively (p<0.001) was noted between control group and A1 group. (p<0.001) was noted between control group and A2 group and (p<0.05) was noted between control group and A3 group. Despite the significant variation between B group and A3 group, glucose level in A3 group (after three weeks of treatment with pycnogenol) could not be reached the normal value. This decreasing could be explained as pycnogenol is a reactive antioxidant able to protect against oxidative stress in several cell systems.

In diabetic patients, the excess amount of glucose could be converted to toxic compounds such as hydrogen peroxide that impair reactive molecules in living cells (lipid peroxidation).

Pycnogenol doubles the intracellular synthesis of antioxidant enzymes such as paraoxonase (PON) and kinases by acting as a potent scavenger of free radicals.

2-Pycnogenol action on total cholesterol (TC) level.

(Figure 2) - Pycnogenol action on total cholesterol (TC) level where:-
C: control group.
B: Patients group before treatment with Pycnogenol.
A1: Patients group after (1 week) of treatment with pycnogenol.
A2: Patients group after (2 weeks) of treatment with pycnogenol.
A3: Patients group after (3 weeks) of treatment with pycnogenol.
Study the action of pycnogenol on glucose and lipid profile in type -2- diabetic patients... Rasha Zuhaier, Dr.Amar Maola Hmod

(Table 2):-The effect of pycnogenol on total cholesterol (TC) in patients group in comparison with control group.

<table>
<thead>
<tr>
<th>subject</th>
<th>No.</th>
<th>M± S.D</th>
<th>t.test</th>
</tr>
</thead>
<tbody>
<tr>
<td>control</td>
<td>30</td>
<td>186±9.5</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>30</td>
<td>230±27.2</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>A1</td>
<td>30</td>
<td>220±14.8</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>A2</td>
<td>30</td>
<td>201±8.3</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>A3</td>
<td>30</td>
<td>191±4.2</td>
<td>P&lt;0.01</td>
</tr>
</tbody>
</table>

M:- TC mean mg/dL  
No. :- number of patients.  
S.D:- standard deviation.  

(Figure 2) and (table 2) represent the reactive antioxidant effect of pycnogenol extract on total cholesterol (TC) level in type-2- diabetic patients. The plasma (TC) in group B was increased (p<0.001) compared with control group (figure 2) and (table 2) because stored lipids are hydrolysed to be used as an energy source instead of glucose , so lipids level will be increased in plasma. (15,16)

After treatment with pycnogenol ,Total cholesterol (TC) level was decreased relatively .(p<0.001) was noted between control group and A1 group. (p<0.001) was noted between control group and A2 group and (p<0.01) was noted between control group and A3 group. This decreasing (after treatment with pycnogenol) are explained as pycnogenol activates enzymes that regulates lipid metabolism and inhibit lipid peroxidation such as kinases and in the same time pycnogenol inhibit enzymes that activate lipid peroxidation such as xanthine oxidase (XO). (15,16)

3-Pycnogenol action on triacylglycerol (TG) level.

(Figure 3) :- Pycnogenol action on triacylglycerol (TG) level where :-  
C:- control group.  
B:- Patients group before treatment with Pycnogenol.  
A1:- Patients group after(1 week) of treatment with pycnogenol.  
A2- Patients group after (2 weeks) of treatment with pycnogenol.  
A3:-Patients group after (3 weeks) of treatment with pycnogenol.
Study the action of pycnogenol on glucose and lipid profile in type-2 diabetic patients...
Rasha Zuhair, Dr. Amar Maola Hmod

(Table 3): - The effect of pycnogenol on triacylglycerol (TG) in patients groups in comparison with control group.

<table>
<thead>
<tr>
<th>subject</th>
<th>No.</th>
<th>M±S.D</th>
<th>t.test</th>
</tr>
</thead>
<tbody>
<tr>
<td>control</td>
<td>30</td>
<td>115±26</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>30</td>
<td>175±35</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>A1</td>
<td>30</td>
<td>155±26</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>A2</td>
<td>30</td>
<td>142±12</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>A3</td>
<td>30</td>
<td>130±8.5</td>
<td>P&lt;0.01</td>
</tr>
</tbody>
</table>

M: - TG mean mg/dL
No.: - number of patients
S.D: - standard deviation

(Figure 3) and (table 3) explain the plasma antioxidant properties of pycnogenol extract on triacylglycerol (TG) level in type-2 diabetic patients. The plasma (TG) in group B was increased (p<0.001) compared with control group (figure 3) and (table 3) because of body dependence on lipids hydrolysis from tissues as an energy source instead of glucose.\(^{(16)}\)

After treatment with pycnogenol, Triacylglycerol (TG) level was decreased relatively (p<0.001) was noted between B control group and A1 group. (p<0.001) was noted between control group and A2 group and (p<0.01) was noted between B control group and A3 group. At this decreasing are explained as pycnogenol activates many enzymes that depress oxidative stress and inhibit enzymes that cause lipid peroxidation.\(^{(16,17)}\)

4- Pycnogenol action on high density lipoproteins level (HDL) level.

(Figure 4) : - Pycnogenol action on high density lipoproteins level where :-
C: - control group.
B: - Patients group before treatment with Pycnogenol.
A1: - Patients group after (1 week) of treatment with pycnogenol.
A2: - Patients group after (2 weeks) of treatment with pycnogenol.
A3: - Patients group after (3 weeks) of treatment with pycnogenol.
Study the action of pycnogenol on glucose and lipid profile in type-2 diabetic patients...
Rasha Zuhair, Dr. Amar Maola Hmod

(Table 4):- The effect of pycnogenol on (HDL) in patients group in comparison with control group.

<table>
<thead>
<tr>
<th>Subject</th>
<th>No.</th>
<th>M± S.D</th>
<th>t.test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>30</td>
<td>46±9.5</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>30</td>
<td>35±27.2</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>A1</td>
<td>30</td>
<td>37±14.8</td>
<td>P&lt;0.01</td>
</tr>
<tr>
<td>A2</td>
<td>30</td>
<td>39±8.3</td>
<td>P&lt;0.01</td>
</tr>
<tr>
<td>A3</td>
<td>30</td>
<td>42±4.2</td>
<td>P&lt;0.05</td>
</tr>
</tbody>
</table>

M:- HDL mean mg/dL
No. :- number of patients.
S.D:- standard deviation.

(Figure 4) and (table 4) represent the important role of pycnogenol on high density lipoproteins (HDL level in type-2 diabetic patients. The plasma (HDL) in group B was decreased (p<0.001) compared with control group (figure 4) and (table 4). This decreasing are explained as the increasing of malondialdehyde level for diabetic patients and decreasing of polyunsaturated fatty acids ratio that lead to increasing of cholesterol ester transfer protein (CETP) activity that transfer cholesterol ester from(HDL) to very low density lipoproteins (VLDL), the result is free (HDL) that is filtrated from the kidney.\(^{(17)}\)

After treatment with pycnogenol, high density lipoproteins (HDL) level was increased relatively .(p<0.01) was noted between control group and A1 group. (p<0.01) was noted between control group and A2 group and (p<0.05) was noted between control group and A3 group. Despite the significant variation between A3 group and control group, HDL level in A3 group (after three weeks of treatment with pycnogenol) could not be reached the normal value. This increasing due to pycnogenol activates paraoxonase (PON) action. The last enzyme found in plasma associating with (HDL). Paraoxonase catalyze hydrolysis of lipid peroxides, cholesteryl linoleate hydroperoxides and organophosphates in oxidized HDL.\(^{(17)}\)

5- Pycnogenol action on low density lipoproteins level.

(Figure 5):- Pycnogenol action on low density lipoproteins (LDL) level where:
- C:- control group.
- B:- Patients group before treatment with Pycnogenol.
- A1:- Patients group after (1 week) of treatment with pycnogenol.
- A2:- Patients group after (2 weeks) of treatment with pycnogenol.
- A3:- Patients group after (3 weeks) of treatment with pycnogenol.
Study the action of pycnogenol on glucose and lipid profile in type -2- diabetic patients...

Rasha Zuhair , Dr.Amar Maola Hmod

(Table 5):-The effect of pycnogenol on (LDL) in patients group in comparison with control group.

<table>
<thead>
<tr>
<th>Subject</th>
<th>No.</th>
<th>M±S.D</th>
<th>t.test</th>
</tr>
</thead>
<tbody>
<tr>
<td>control</td>
<td>30</td>
<td>116±12.1</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>30</td>
<td>165±28.1</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>A1</td>
<td>30</td>
<td>150±18.6</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>A2</td>
<td>30</td>
<td>142±11.2</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>A3</td>
<td>30</td>
<td>130±11.2</td>
<td>P&lt;0.01</td>
</tr>
</tbody>
</table>

M:- LDL mean (mg/dL).
No. :- number of patients.
S.D:- standard deviation

(Figure 5) and (table 5) represent the important effect of pycnogenol on low density lipoproteins (LDL) level in type-2- diabetic patients. The plasma (LDL) in group B was increased (p<0.001) compared with control group (figure 5) and (table 5). Because of the elevation of lipid peroxidation that causes an impairment of (LDL) receptors in cellular membranes (oxidative modification of (LDL) and precipitation in arterial walls. (18)

After treatment with pycnogenol ,low density lipoproteins (LDL) level was decreased relatively (p<0.001) was noted between control group and A1 group. (p<0.001) was noted between control group and A2 group and (p<0.01) was noted between control group and A3 group. This decreasing are explained as pycnogenol is a reactive antioxidatb that depress oxidative stress maximally by activating enzymes that inhibit lipid peroxidation such as activated monoprotein kinase (AMP) and inhibit enzymes that activate oxidative stress such as phosphodiesterase. (19,20)

6- Pycnogenol action on very low density lipoprotiliens level.

(Figure 6) :- Pycnogenol action on very low density lipoprotiliens (VLDL) level where:-
C:- control group.
B:-Patients group before treatment with Pycnogenol.
A1:- Patients group after(1 week) of treatment with pycnogenol.
A2:- Patients group after (2 weeks) of treatment with pycnogenol.
A3:- Patients group after (3 weeks) of treatment with pycnogenol.
Study the action of pycnogenol on glucose and lipid profile in type-2 diabetic patients...

Rasha Zuhair, Dr. Amar Maola Hmod

(Table 6): The effect of pycnogenol on (VLDL) in patients group in comparison with control group

<table>
<thead>
<tr>
<th>Subject</th>
<th>No.</th>
<th>M±S.D</th>
<th>t.test</th>
</tr>
</thead>
<tbody>
<tr>
<td>control</td>
<td>30</td>
<td>23±4.8</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>30</td>
<td>32±7.9</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>A1</td>
<td>30</td>
<td>30±5.9</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>A2</td>
<td>30</td>
<td>28±3.1</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>A3</td>
<td>30</td>
<td>27±2.3</td>
<td>P&lt;0.01</td>
</tr>
</tbody>
</table>

M:- VLDL mean (mg/dL)
No. :- number of patients.
S.D:- standard deviation

(Figure 6) and (table 6)) represent the reactive action of pycnogenol on very low density lipoproteins (VLDL) level in type-2 diabetic patients. The plasma (VLDL) in group B was increased (p<0.001) compared with control group (figure 6) and (table 6).

After treatment with pycnogenol, very low density lipoproteins (VLDL) level was decreased relatively (p<0.001) was noted between control group and A1 group. (p<0.001) was noted between control group and A2 group and (p<0.01) was noted between control group and A3 group. Triacylglycerol (TG) is an important component (VLDL). So, the above results could be explained just like pycnogenol action on (TG) level.\(^{16,17}\)

**Conclusion :-**
1- Glucose level decreases relatively after treatment with pycnogenol for type-2 diabetes patients. (glucose correlates positively with oxidative stress).
2- Total cholesterol (TC), Triacylglycerol (TG), Low density lipoproteins (LDL) and very low density lipoproteins (VLDL) levels decreases relatively after treatment with Pycnogenol for type-2 diabetes patients. (These parameters correlates positively with oxidative stress).
3- High density lipoproteins (HDL) level increases relatively after treatment with Pycnogenol for type-2 diabetes patients. (HDL correlates negatively with oxidative stress).

**References :-**
Study the action of pycnogenol on glucose and lipid profile in type 2 diabetic patients...

Rasha Zuhair, Dr. Amar Maola Hmod


Study the action of pycnogenol on glucose and lipid profile in type-2 diabetic patients...

Rasha Zuhair, Dr. Amar Maola Hmod

Dr. Umair Mohiud

Department of Applied Sciences and Technology, College of Education, Ibn Hanequin University

Research Center for Biotechnology and Food Engineering.

Summary:

The action of pycnogenol on glucose and lipid profile in type 2 diabetic patients was studied. The research was conducted on 30 diabetic patients who were divided into two groups: control and treatment. The control group was on a normal diet, while the treatment group was given pycnogenol in addition to their normal diet. The study lasted for three months. The results showed a significant decrease in blood glucose and lipid levels in the treatment group compared to the control group. The decrease was statistically significant at a level of p<0.001. The study concluded that pycnogenol can be used as an adjuvant to conventional treatment of type 2 diabetes.

The abstract in Arabic:

دراسة تأثير البایسنوجنول على سكر الكلوكوز والدهون في المرضى المصابين بالنوع الثاني للسكري.

م. عمار موحى حوىد

وزارة العلوم والتكنولوجيا

مركز بحوث الكيوياء

الخلاصة:

تم استخدام البایسنوجنول (المستخلص المائي المكون من المركبات متعددة الفينول) من لحاء الصبر عراقي المنشأ وتم تحليله باستخدام كروموتوغرافيا السائل ذات الكفاءة العالية المترافقة مع طيف الأشعة فوق البنفسجية عند الطول الموجي (254 نانومتر).

أظهرت النتائج أن مستوى الكولسترول الكلى و السكري مهمة، والكليسترولات الثلاثية والبروتينات الدقيقة عالى الكثافة والبروتينات الدقيقة ضئيلة الكثافة والبروتينات الدقيقة ضئيلة الكثافة (3 مريضا مصابا بالسكرى) الذين تمت معالجتهم بعنبات ورانية (500 ملم) من البایسنوجنول ثلاث مرات يوميا لاستخدام الدور الغذائي للبایسنوجنول ضد شدة الأكيد. إن مستوى الكريستالون الكلى أعلى عند الفينول الحر في البالاغان متابعة البایسنوجنول وعند مرور أسبوع (وأسبوعين) و (ثلاثة أسابيع) من العلاج.

الخلاصة:

إن مستوى الكوليسترول الكلى يرفع نسبة لدى مرضى السكري المقارنة مع مجموعة البایسنوجنول. (0.01<p<0.001) بعد أسبوع و (0.01<p<0.001) بعد ثلاثة أسابيع من العلاج.

إن مستوى الكليسترولات الثلاثية ي زداد نسبة لدى المصابين بالسكري مقارنة مع مجموعة البایسنوجنول (0.01<p<0.001) ولكن بعد المعالجة بهذا المركب الغذائي فإن مستوى البایسنوجنول في معالجة البایسنوجنول بعد أسبوع (0.01<p<0.001) بعد أسبوع و (0.01<p<0.001) بعد ثلاثة أسابيع من العلاج.

إن مستوى البروتينات عالية الكثافة ي زداد نسبة لدى المصابين بالسكري مقارنة مع مجموعة البایسنوجنول (0.01<p<0.001) ولكن بعد العلاج بالبایسنوجنول فإن مستوى البروتينات عالية الكثافة ي زداد نسبة (0.01<p<0.001) بعد أسبوع و (0.01<p<0.001) بعد ثلاثة أسابيع من العلاج.

إن مستوى البروتينات تحت الكثافة ي زداد نسبة لدى المصابين بالسكري المقارنة مع مجموعة البایسنوجنول (0.01<p<0.001) ولكن بعد العلاج بالبایسنوجنول فإن مستوى البروتينات تحت الكثافة ي زداد نسبة (0.01<p<0.001) بعد أسبوع و (0.01<p<0.001) بعد ثلاثة أسابيع من العلاج.

إن مستوى البروتينات ضئيلة الكثافة ي زداد نسبة لدى المصابين بالسكري مقارنة مع مجموعة البایسنوجنول (0.01<p<0.001) ولكن بعد العلاج بالبایسنوجنول فإن مستوى البروتينات ضئيلة الكثافة ي زداد نسبة (0.01<p<0.001) بعد أسبوع و (0.01<p<0.001) بعد ثلاثة أسابيع من العلاج.